The University of Michigan's medical school recently toughened its conflict of interest rules by barring pharmaceutical industry funding to support continuing medical education. That leaves some wondering why the university's president, Mary Sue Coleman, sits on the board of Johnson & Johnson, The Detroit Free Press reported. Coleman sees the situations as different, noting that she is not involved with the kinds of decisions at the medical school that could directly involve Johnson & Johnson's products. "It's essential that U-M have a voice and interact with the business world," a university spokesman told the Free Press. "She thinks it's her duty to understand what the commercial world is doing."
- Still Fighting for Affirmative Action
- Concern Over Michigan Tenure Case
- More Aid at Michigan
- Quick Takes: Ind. Students Killed in Plane Crash, Asians Top Whites at U. of Calif., CEO Accused of Harassment Quits, Michigan Drug Benefit, Miss. Crackdown on Diploma Mills, Court Rejects Challenge to Calif. Stem Cell Center, Plan on Loan Tax Credit
- Stem Cells Meet Google
- Lawmaker blasts colleague over perceived intrusion into social science funding
- 'A Good Investment'
- A Different Diversity Debate
Search for Jobs